ArticleThe Journal of surgical research2009
Pharmacological synergism between cannabinoids and paclitaxel in gastric cancer cell lines.
Article in The Journal of surgical research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 73 citations in OpenAlex.
- Review
- Pro-Apoptotic Effects of Anandamide in Human Gastric Cancer Cells Are Mediated by AKT and ERK Signaling Pathways.International journal of molecular sciences · 2025Article
- CBD promotes antitumor activity by modulating tumor immune microenvironment in HPV associated head and neck squamous cell carcinoma.Frontiers in immunology · 2025Article
- Research mapping of cannabinoids and endocannabinoid system in cancer over the past three decades: insights from bibliometric analysis.Frontiers in pharmacology · 2025Article
- Exploring the therapeutic potential of cannabinoids in cancer by modulating signaling pathways and addressing clinical challenges.Discover oncology · 2024Review
- The potential neuroprotective effects of cannabinoids against paclitaxel-induced peripheral neuropathy:Frontiers in pharmacology · 2024Article
- Review
- Cannabinoids as anticancer drugs: current status of preclinical research.British journal of cancer · 2022Review
- Cannabinoids orchestrate cross-talk between cancer cells and endothelial cells in colorectal cancer.Cancer gene therapy · 2022Article
- Can Cannabidiol Affect the Efficacy of Chemotherapy and Epigenetic Treatments in Cancer?Biomolecules · 2021Review
- Medical Cannabis in Oncology: a Valuable Unappreciated Remedy or an Undesirable Risk?Current treatment options in oncology · 2021Review
- Emerging Roles of Cannabinoids and Synthetic Cannabinoids in Clinical Experimental Models.Advances in experimental medicine and biology · 2021Review
- Cannabinoids Promote Progression of HPV-Positive Head and Neck Squamous Cell Carcinoma via p38 MAPK Activation.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Article
- The Endocannabinoid System as a Target in Cancer Diseases: Are We There Yet?Frontiers in pharmacology · 2019Review
- Antitumor Activity of Abnormal Cannabidiol and Its Analog O-1602 in Taxol-Resistant Preclinical Models of Breast Cancer.Frontiers in pharmacology · 2019Article
- Insights into the effects of the endocannabinoid system in cancer: a review.British journal of pharmacology · 2018Review
- A user's guide to cannabinoid therapies in oncology.Current oncology (Toronto, Ont.) · 2016Review
- Anticancer mechanisms of cannabinoids.Current oncology (Toronto, Ont.) · 2016Review
- Anti-carcinogenic activity of anandamide on human glioma in vitro and in vivo.Molecular medicine reports · 2016Article
- Endocannabinoids are conserved inhibitors of the Hedgehog pathway.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Orally applicable Delta9-tetrahydrocannabinol and its synthetic derivatives have been used as antiemetic drugs during chemotherapy in cancer patients. However, it is not well known how cannabinoids influence the effects of chemotherapeutic agents on malignant tumors. In this study, we investigated how the endogenous cannabinoid anandamide (AEA) changes the effect of paclitaxel on gastric cancer cell lines. In the human gastric cancer cell line, HGC-27, which express cannabinoid receptor 1 (CB1), AEA stimulated proliferation at concentrations under 1 microM, while it strongly suppressed proliferation through the induction of apoptosis at 10 microM. This bimodal effect was reproduced by a selective CB1 agonist, arachidonyl-2-chloroethylamide, although the effects were less marked. When AEA was used with paclitaxel, AEA at 10 microM synergistically enhanced the cytotoxic effect of paclitaxel, whereas it showed no significant effect at lower concentrations. Flow cytometric analysis revealed that addition of 10 microM AEA synergistically enhanced paclitaxel-induced apoptosis, possibly through the activation of caspase-3, -8, and -9. Our results suggest that cannabinoids could be a good palliative agent for cancer patients receiving paclitaxel.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.